RxDoctor Payments Data

Carolann Brooks

Psychiatric/Mental Health · Celebration, FLNPI 1770807687

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $48,535 of the $57,460 with a category attached, or 84.5%. AbbVie accounts for 84.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $30,866 and has fallen 90.4% since, to $2,953 in 2025. Among psychiatric/mental health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$57,460in general payments, 2019–2025

Across 356 payments — averaging $161.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$48K
  • Otsuka America Pharmaceutical, Inc.$6K
  • Corium, LLC$541
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$457
  • Alkermes, Inc.$417
  • Takeda Pharmaceuticals U.S.A., Inc.$412
  • plus $904 from 9 others

What the payments were for

  • Speaking & faculty fees$48,53584%
  • Travel & lodging$3,4546%
  • Food & beverage$5,4229%
  • Education$490%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,460 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$20,415
Medicare patients
25
Services billed
226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl26$53,033
Aripiprazole33$4,705
Bupropion XlBupropion Hcl45$729
Escitalopram Oxalate72$592
Methylphenidate Hcl20$589
Alprazolam69$500
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$472
Duloxetine Hcl22$465
Lamotrigine30$377
Quetiapine Fumarate16$374
Clonazepam23$349
Eszopiclone12$320
Zolpidem Tartrate26$315
Olanzapine25$314
Bupropion Hcl SrBupropion Hcl16$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$48,279$53,03326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Celebration

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →